ChAdOx1 LS2

Phase 2Biologic

EEuBiologics Co.,Ltd

ChAdOx1 LS2 is one of 3 biologic programs targeting Rift Valley Fever. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rift Valley FeverActive, not recruiting

Rift Valley FeverPhase 2

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Rift Valley Fever

#DrugCompanyPhaseTrials

Rabies Vaccine

Novartis

Phase 2

1 2

ChAdOx1 LS2

EEuBiologics Co.,Ltd

Phase 2

2 3

RVF MP-12

UU.S. Army Medical Research and Development Command

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Rift Valley Fever

NCT06799234

Clinical

Trials by Indication[1]

COVID-196 trials

A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults

Completed·EEuBiologics Co.,Ltd·Phase 3·NCT05572879·2,600 enrolled

Investigating a Vaccine Against COVID-19

Completed·UUniversity of Oxford·Phase 2/3·NCT04400838·10,811 enrolled

A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older

Completed·EEuBiologics Co.,Ltd·Phase 3·NCT05603052·2,852 enrolled

Show 3 more trials

COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection

Unknown status·UUniversity of Oxford·Phase 1/2·NCT04444674·2,130 enrolled

A Study of a Candidate COVID-19 Vaccine (COV003)

Unknown status·UUniversity of Oxford·Phase 3·NCT04536051·10,300 enrolled

A Study of a Candidate COVID-19 Vaccine (COV001)

Completed·UUniversity of Oxford·Phase 1/2·NCT04324606·1,077 enrolled

Immunogenicity5 trials

Safety and Immunogenicity of a Candidate ZIKV Vaccine (ZIKA001)

Completed·UUniversity of Oxford·Phase 1·NCT04015648·24 enrolled

Safety and Immunogenicity of a Candidate CHIKV Vaccine (CHIK001)

Completed·UUniversity of Oxford·Phase 1·NCT03590392·24 enrolled

Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)

Terminated·UUniversity of Oxford·Phase 1·NCT03399578·29 enrolled

Show 2 more trials

A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine (MERS002)

Completed·KKing Abdullah International Medical Research Center·Phase 1·NCT04170829·24 enrolled

Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001)

Completed·UUniversity of Oxford·Phase 1·NCT04754776·15 enrolled

Rift Valley Fever2 trials

A Study to Assess the New Candidate Rift Valley Fever Virus Vaccine in Healthy Adults

Completed·UUniversity of Oxford·Phase 1·NCT04672824·30 enrolled

Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)

Active, not recruiting·UUniversity of Oxford·Phase 2·NCT06799234·240 enrolled

Vaccine2 trials

A Study of a New Vaccine Against Two Types of Ebola

Completed·UUniversity of Oxford·Phase 1·NCT05079750·26 enrolled

A Study in Tanzania of a New Vaccine Against Two Types of Ebola

Unknown status·UUniversity of Oxford·Phase 1·NCT05301504·76 enrolled

Vaccination1 trial

Safety Study of ChAdOx1 85A Vaccination With and Without MVA85A Boost in Healthy Adults

Completed·UUniversity of Oxford·Phase 1·NCT01829490·42 enrolled

2 more indications

Safety and Efficacy1 trial

A Safety and Efficacy Study of ChAdOx1 LS2 and MVA LS2

Completed·UUniversity of Oxford·Phase 1/2·NCT03203421·18 enrolled

Unspecified1 trial

A Study of Intranasal ChAdOx1 nCOV-19

Completed·UUniversity of Oxford·Phase 1·NCT04816019·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for ChAdOx1 LS2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ChAdOx1 LS2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ChAdOx1 LS2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EuBiologics Co.,Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: EEuBiologics Co.,Ltd

ChAdOx1 LS2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

COVID-196 trials

Immunogenicity5 trials

Rift Valley Fever2 trials

Vaccine2 trials

Vaccination1 trial

Safety and Efficacy1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News